Krystal expands commercial gene therapy production

January 28, 2020 -- Krystal Biotech on January 24 announced the beginning of construction on its second commercial gene therapy facility in Findlay Township in Pennsylvania. The facility will have the capacity to produce commercial gene therapy medicines for a variety of rare diseases.

The Current Good Manufacturing Practice (cGMP) facility, named ASTRA, expands on Krystal's current production capabilities, with in-house incorporation of raw material preparation, excipient manufacturing, testing, packaging, labeling, and distribution. ASTRA will fully integrate all components in the supply chain from starting materials to patient experience.

Over the next 12 to 15 months, validation throughout the 100,000-sq-ft space will occur. The state-of-the-art facility will initially be used as a commercial backup facility for bercolagene telserpavec (B-VEC), a gene therapy for treatment for dystrophic epidermolysis bullosa.

After the initial phase, Krystal plans to expand the use of the facility to produce investigational and commercial materials for its pipeline products. Upon opening, the facility will create 75 to 200 new jobs in biologics manufacturing.

Joint venture targets cell and gene therapy
A new joint venture dedicated to supporting researchers and biopharmaceutical companies in cell and gene therapy was announced on January 21. The joint...

Copyright © 2020

International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
Interphex 2022 Conference
May 24-26
New York, New York United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter